Abstract
Objective: In this study, a randomized and placebo controlled trial, we aimed to study the effectiveness and safety of doxazosin based upon urodynamic parameters, especially pressure/flow studies, in men with benign prostatic hyperplasia (BPH).
Materials and methods: A total of 57 men (29 doxazosin, 28 placebo) 48–82 years of age with BPH were enrolled. Yet, 8 of 29 in the doxazosin group and 10 of 28 in the placebo group were excluded due to side effects of doxazosin and intolerability of urodynamic assessment of free uroflow, postvoiding residual-urine volume (PVR) and pressure/flow studies.
Results: There were improvements in all urodynamic parameters (Free Qmax: 30.4% and 28%, PVR: 14 ml and 12 ml, invasive Qmax: 29.3% and 26.2%, Pdet at Qmax: −32.7% and −30%, Pdet-max: −29% and −27.7% at end of the 1st and 6th months whereas placebo effects were worsening in all urodynamic parameters.
Conclusions: We suggest that doxazosin is an important treatment option for patients with BPH, and efficacy of doxazosin should be evaluated with objective, quantitative urodynamic studies not with subjective symptom scores. But additional costs and invasiveness of urodynamic studies restrict their common usefulness.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boyle, P.: Epidemiology of benign prostatic hyperplasia: Risk factors and concomitance with hypertension. Br. J. Clin. Pract., 74(Suppl.), 18 (1994).
Mc Connel, J. D., Barry, M. J., Bruskewitz, R. C., Bueschen, A. J., Denton, S. E., Haltgrewe, H. L., Lange, J. L., Mc Clennon, B. L., Mebust, W. K., Reilly, N. J., Roberts, R. G., Sacks, S. A., Wasson, J. H.: Benign prostatic hyperplasia: Diagnosis and treatment. Quick reference guide for clinicians. AHCPR Publ No 94–0583. Rockville, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, February 1994.
The 3rd International Consultation on BPH: Recommendations of the International Consensus Committee. In: Cockett, A. T. K., Khoury, S., Aso, Y., Chatclain, C., Denis, L., Griffiths, K., Murphy, G. (eds): Proceedings of the 3rd International Consultation on BPH, Monaco, June 26–28, 1995. Channel Islands, Scientific Communication International, 1996, pp. 625–640.
Jimenez, C. J. F.: The role of alpha-adrenergic blockers in the treatment of prostatic hypertrophy. Drugs Today, 29, 343 (1993).
Barry, M. J., Mulley, A. G., Fowler, F. J., Wennberg, J. W.: Watchful waiting versus immediate transurethral resection for symptomatic prostatism: The importance of patients' references. JAMA, 259, 3010 (1988).
Fowler, F. J., Jr., Wennberg, J. E., Timothy, R. P., Barry, M. J., Mulley, A. G., Jr., Hanley, D.: Symptom status and quality of life following prostatectomy. JAMA, 259, 3018 (1988).
Ross, N. P., Wennberg, J. E., Malenka, D. J., Fisher, E. S., Mc Pherson, K., Andersen, T. F., Cohen, M. M., Ramsey, E.: Mortality and reoperation after open and transurethral resection of prostate for benign prostatic hyperplasia. N. Engl. J. Med., 320, 1120 (1989).
Kirby, R. S., Coppinfer, S. W. L., Corcoran, M. O., Chapple, C. R., Flannagan, M., Nilroy, E. J. G.: Prazosin in the treatment of prostatic obstruction: A placebo-controlled study. Br. J. Urol., 60, 136 (1987).
Chapple, C. R., Christmas, T. J., Milroy, E. J.: A twelve-week, placebo controlled study of prazosin in the treatment of prostatic obstruction. Urol. Int., 45(Suppl 1), 47 (1990).
Fawzy, A., Braun, K., Lewis, G. P., Gaffrey, M., Ice, K., Dias, N., for the multicenter study group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J. Urol., 154, 105 (1995).
Caine, M., Pfan, A., Pelberg, S.: The use of alpha-adrenergic blockers in benign prostatic obstruction. Br. J. Urol., 47, 255 (1976).
Lepor, H.: Medical therapy for BPH. Urology, 42, 483 (1993).
Perlberg, S., Caine, M.: Adrenergic response of bladder muscle in prostatic obstruction: Its relation to detrusor instability. Urology, 20, 524 (1982).
McConnel, J. D.: Epidemiology, etiology, pathophysiology and diagnosis of benign prostatic hyperplasia. In: Walsh, P. C., Retik, A. B., Vaughan, E. D., Wein, A. J. (eds): Campbell's Urology. Seventh edition. W. B. Saunders Co., Philadelphia 1998, p. 1429.
Abrams, P.: Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction: Results from three double-blind placebo controlled studies. European Urology, 32/1, 39 (1997).
Hedlung, A., Andersson, K. E., Ek, A.: Effects of prazosin in patients with benign prostatic obstruction. J. Urol., 130, 275 (1983).
Christensen, M. M., Holme, J. B., Rasmussen, P. C.: Doxazosin treatment in patients with prostatic obstruction, a double-blind, placebo controlled study. Scand. J. Urol. Nephrol., 27(1), 39 (1993).
Holme, J. B., Christensen, M. M., Rasmussen, P. C.: 29 week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia, a double-blind, placebo controlled study. Scand. J. Urol. Nephrol., 28, 77 (1994).
Janknegt, R. A., Chapple, C. R.: Efficacy and safety of the alpha I-blocker doxazosin in treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur. Urol., 24(3), 319 (1993).
Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K., Dias, N., for the multicenter study group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo controlled, dose-response multicenter study. J. Urol., 154, 110 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Özbey, I., Aksoy, Y., Polat, Ö. et al. Effects of Doxazosin in Men with Benign Prostatic Hyperplasia: Urodynamic Assessment. Int Urol Nephrol 31, 471–479 (1999). https://doi.org/10.1023/A:1007111211130
Issue Date:
DOI: https://doi.org/10.1023/A:1007111211130